Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> AMGEN Latest News

JAN 16, 2013 - Forbes

A Must Read - Share

Amgen Trial Fails To Show Benefit Of Anemia Drug In Heart Failure Patients

The bad news continues for Aranesp (darbepoetin alfa), Amgen's long-acting erythropoietin-stimulating agent. The drug is intended to stimulate red cell blood production in patients with anemia. Amgen today announced the top line results of a large phase 3 heart failure trial of the drug and said  the trial had failed to meet its primary endpoint.

Tags: Amgen Trial Fails To Show Benefit Of Anemia Drug In Heart Failure Patients,  Amgen Latest News